{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T15:58:39Z","timestamp":1774454319298,"version":"3.50.1"},"posted":{"date-parts":[[2026,2,22]]},"group-title":"In Review","reference-count":25,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T00:00:00Z","timestamp":1771718400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,2,10]]},"abstract":"<title>Abstract<\/title>\n                <p>Background: We previously reported results from a randomized phase 2 trial evaluating a DNA vaccine (pTVG-HP) versus placebo (GM-CSF vaccine adjuvant alone) in patients with PSA-recurrent, non-metastatic, non-castrate prostate cancer (NCT01341652). The primary endpoint of 2-year metastasis-free survival (MFS) was not different between the treatment arms. This trial was reopened for long-term evaluation at one study site.\nMethods and Results: The median follow-up for long-term overall survival was 4.1 years (range 0.1-13.8+ years). Median overall survival of 48 patients treated with pTVG-HP was 13.4 years versus 8.6 years for 49 patients treated with placebo (log-rank test p-value=0.020). Long-term follow-up information on survival and subsequent treatments was available for 59 patients. Of these, 56 were treated with subsequent androgen deprivation therapy (ADT). When analyzing overall survival for this cohort, the adjusted hazard ratio was 0.56 (p=0.021) when comparing pTVG-HP vs. placebo, after adjusting for ADT and subsequent treatment exposure. The median time to beginning ADT was 2.2 years for patients randomized to pTVG-HP versus 1.4 years for patients randomized to placebo (p=0.192). The median time to the next therapy for castration-resistant disease after beginning ADT was 4.7 years for patients randomized to pTVG-HP versus 2.1 years for patients randomized to placebo (p=0.112).\nConclusions: These results suggest that pTVG-HP may have had single-agent benefit that could not be appreciated using a MFS endpoint, challenging the notion that MFS can uniformly serve as a surrogate endpoint for overall survival in this stage of disease.<\/p>","DOI":"10.21203\/rs.3.rs-8843559\/v1","type":"posted-content","created":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T16:33:56Z","timestamp":1771778036000},"source":"Crossref","is-referenced-by-count":0,"title":["Progression-Free Survival versus Overall Survival in Patients with PSA-Recurrent Prostate Cancer: Long-Term Analysis of a Randomized Phase 2 Trial of pTVG-HP versus Placebo"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1471-6723","authenticated-orcid":false,"given":"Douglas","family":"McNeel","sequence":"first","affiliation":[{"name":"University of Wisconsin Comprehensive Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Eickhoff","sequence":"additional","affiliation":[{"name":"University of Wisconsin-Madison"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn","family":"Liu","sequence":"additional","affiliation":[{"name":"University of Wisconsin-Madison"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0022-5347(01)64243-5","article-title":"Long-term results of radical retropubic prostatectomy in men with high grade carcinoma of the prostate","volume":"158","author":"Oefelein MG","year":"1997","unstructured":"Oefelein MG, Smith ND, Grayhack JT, et al: Long-term results of radical retropubic prostatectomy in men with high grade carcinoma of the prostate. J Urol 158:1460\u20131465, 1997","journal-title":"J Urol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","article-title":"Natural history of progression after PSA elevation following radical prostatectomy","volume":"281","author":"Pound CR","year":"1999","unstructured":"Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. Jama 281:1591\u20137., 1999","journal-title":"Jama"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/cncr.26437","article-title":"Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials","volume":"118","author":"Antonarakis ES","year":"2012","unstructured":"Antonarakis ES, Zahurak ML, Lin J, et al: Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials. Cancer 118:1533\u201342, 2012","journal-title":"Cancer"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial","volume":"6","author":"Phillips R","year":"2020","unstructured":"Phillips R, Shi WY, Deek M, et al: Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol 6:650\u2013659, 2020","journal-title":"JAMA Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer","volume":"389","author":"Freedland SJ","year":"2023","unstructured":"Freedland SJ, de Almeida Luz M, De Giorgi U, et al: Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. N Engl J Med 389:1453\u20131465, 2023","journal-title":"N Engl J Med"},{"key":"ref6","article-title":"Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer","author":"Shore ND","year":"2025","unstructured":"Shore ND, Luz MA, De Giorgi U, et al: Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. N Engl J Med, 2025","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1200\/JCO.19.01701","article-title":"Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer","volume":"37","author":"McNeel DG","year":"2019","unstructured":"McNeel DG, Eickhoff JC, Johnson LE, et al: Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer. J Clin Oncol 37:3507\u20133517, 2019","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1200\/JCO.2008.19.9968","article-title":"Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer","volume":"27","author":"McNeel DG","year":"2009","unstructured":"McNeel DG, Dunphy EJ, Davies JG, et al: Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 27:4047\u201354, 2009","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2395680","DOI":"10.1080\/21645515.2024.2395680","article-title":"Long-term follow up of patients treated with a DNA vaccine (pTVG-hp) for PSA-recurrent prostate cancer","volume":"20","author":"Tonelli TP","year":"2024","unstructured":"Tonelli TP, Eickhoff JC, Johnson LE, et al: Long-term follow up of patients treated with a DNA vaccine (pTVG-hp) for PSA-recurrent prostate cancer. Hum Vaccin Immunother 20:2395680, 2024","journal-title":"Hum Vaccin Immunother"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41391-024-00894-0","article-title":"Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment","volume":"28","author":"Freedland SJ","year":"2025","unstructured":"Freedland SJ, Gao W, Lax A, et al: Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment. Prostate Cancer Prostatic Dis 28:809\u2013816, 2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-01693","article-title":"National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations","author":"Einstein DJ","year":"2025","unstructured":"Einstein DJ, Abel ML, Aragon-Ching JB, et al: National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations. J Clin Oncol:JCO2501693, 2025","journal-title":"J Clin Oncol:JCO2501693"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"EVIDoa2300251","DOI":"10.1056\/EVIDoa2300251","article-title":"Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer","volume":"2","author":"Freedland SJ","year":"2023","unstructured":"Freedland SJ, Gleave M, De Giorgi U, et al: Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer. NEJM Evid 2:EVIDoa2300251, 2023","journal-title":"NEJM Evid"},{"key":"ref13","first-page":"16","article-title":"How the Management of Biochemical Recurrence in Prostate Cancer Will Be Modified by the Concept of Anticipation and Incrementation of Therapy","author":"Sciarra A","year":"2024","unstructured":"Sciarra A, Santarelli V, Salciccia S, et al: How the Management of Biochemical Recurrence in Prostate Cancer Will Be Modified by the Concept of Anticipation and Incrementation of Therapy. Cancers (Basel) 16, 2024","journal-title":"Cancers (Basel)"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1470-2045(20)30730-0","article-title":"Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis","volume":"22","author":"Gharzai LA","year":"2021","unstructured":"Gharzai LA, Jiang R, Wallington D, et al: Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. The Lancet Oncology 22:402\u2013410, 2021","journal-title":"The Lancet Oncology"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff PW","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411\u201322, 2010","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/cncr.24429","article-title":"Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer","volume":"115","author":"Higano CS","year":"2009","unstructured":"Higano CS, Schellhammer PF, Small EJ, et al: Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115:3670\u20139, 2009","journal-title":"Cancer"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","article-title":"Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer","volume":"24","author":"Small EJ","year":"2006","unstructured":"Small EJ, Schellhammer PF, Higano CS, et al: Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24:3089\u201394, 2006","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1634\/theoncologist.2010-0129","article-title":"Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression","volume":"15","author":"Madan RA","year":"2010","unstructured":"Madan RA, Gulley JL, Fojo T, et al: Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist 15:969\u201375, 2010","journal-title":"Oncologist"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.urology.2013.01.061","article-title":"Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial","volume":"81","author":"Schellhammer PF","year":"2013","unstructured":"Schellhammer PF, Chodak G, Whitmore JB, et al: Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology 81:1297\u2013302, 2013","journal-title":"Urology"},{"key":"ref20","author":"Petrylak D","year":"2006","unstructured":"Petrylak D: Defiing the optimal role of immunotherapy and chemotherapy: Advanced prostate cancer patients who receive Sipuleucel-T (PROVENGE) followed by docetaxel derive the greatest survival benefit. Presented at the 14th Annual Meeting of the Chemotherapy Foundation Symposium, New York, NY, 2006"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1158\/1078-0432.CCR-06-2937","article-title":"Granulocyte macrophage colony-stimulating factor\u2013secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer","volume":"13","author":"Small EJ","year":"2007","unstructured":"Small EJ, Sacks N, Nemunaitis J, et al: Granulocyte macrophage colony-stimulating factor\u2013secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 13:3883\u201391, 2007","journal-title":"Clin Cancer Res"},{"key":"ref22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008848","article-title":"Sequence of androgen receptor-targeted vaccination with androgen deprivation therapy affects anti-prostate tumor efficacy","volume":"12","author":"Muralidhar A","year":"2024","unstructured":"Muralidhar A, Gamat-Huber M, Vakkalanka S, et al: Sequence of androgen receptor-targeted vaccination with androgen deprivation therapy affects anti-prostate tumor efficacy. J Immunother Cancer 12, 2024","journal-title":"J Immunother Cancer"},{"key":"ref23","first-page":"vii91-5","article-title":"Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer","volume":"7","author":"Sternberg CN","year":"2008","unstructured":"Sternberg CN: Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer. Ann Oncol 19 Suppl 7:vii91-5, 2008","journal-title":"Ann Oncol 19 Suppl"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"5162","DOI":"10.1158\/1078-0432.CCR-20-0945","article-title":"Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer","volume":"26","author":"Kyriakopoulos CE","year":"2020","unstructured":"Kyriakopoulos CE, Eickhoff JC, Ferrari AC, et al: Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer. Clin Cancer Res 26:5162\u20135171, 2020","journal-title":"Clin Cancer Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1089\/cbr.2014.1805","article-title":"Cancer Vaccines: Can They Improve Survival?","volume":"30","author":"Dillman RO","year":"2015","unstructured":"Dillman RO: Cancer Vaccines: Can They Improve Survival? Cancer Biotherapy and Radiopharmaceuticals 30:147\u2013151, 2015","journal-title":"Cancer Biotherapy and Radiopharmaceuticals"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8843559\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8843559\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T15:23:05Z","timestamp":1774452185000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8843559\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,22]]},"references-count":25,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-8843559\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,2,22]]},"subtype":"preprint"}}